New drug combo aims to fight colorectal cancer when standard chemo fails
NCT ID NCT07286695
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether a new drug combination (fruquintinib plus trifluridine/tipiracil) works better than a standard combo (bevacizumab plus trifluridine/tipiracil) for people with advanced colorectal cancer that has not responded to standard chemotherapy. About 292 adults aged 18-75 will be randomly assigned to one of the two treatments. The main goal is to see how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- fruquintinib combined with trifluridine/tipiracil
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced colorectal cancer who have run out of standard chemotherapy options.
- What could go wrong
- This is an early Phase 2 trial with only 292 participants, so results may not confirm benefit. The combination may cause side effects like those seen with similar drugs, and it may not improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?